RESULTS
hair loss, FAGA
MAY, HAIR LOSS
Between May 2022 and November 2022, 83 subjects with AGA, FAGA or chronic TE were assessed and screened for inclusion in the trial. Demographics and baseline characteristic were similar between groups (Table Demographics and baseline characteristics.Seventy‐six participants completed the trial (91.6%), and seven subjects stopped prematurely the trial for different reasons (Figure Study's flow.Patients, both in group A and group B received different drug treatments according to the type of hair loss. Topical Minoxidil (2% and 5%) was the treatment most used (Table Distribution of drug treatments, alone or in combination with the food supplement used in this study, decided by the investigators according to the type of hair loss.